Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacotherapy for erectile dysfunction.

Harin Padma-Nathan1, George Christ, Ganesan Adaikan

  • 1hpn@insyght.com

The Journal of Sexual Medicine
|January 21, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relative Impact of Male Urinary Conditions on Overall Quality of Life.

Neurourology and urodynamics·2025
Same author

Editorial Commentary.

Urology practice·2024
Same author

Factors affecting post-vasectomy semen analysis compliance in home- and lab-based testing.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada·2023
Same author

[Special diagnostics in pediatric urology-Ultrasound, VCUG, CT and MRI : Part 1: tips for the practice].

Urologie (Heidelberg, Germany)·2022
Same author

Development and pre-clinical test of a phosphorous-32 containing polyetheretherketone foil aiming at urethral stricture prevention by low-dose-rate brachytherapy.

Journal of contemporary brachytherapy·2022
Same author

Accuracy and prognostic value of radiological lymph node features in variant histologies of bladder cancer.

World journal of urology·2022
Same journal

Vagina-sparing metoidioplasty: technique and outcomes.

The journal of sexual medicine·2026
Same journal

Testosterone prescription rates in gay and bisexual men with erectile dysfunction: a cross-sectional study.

The journal of sexual medicine·2026
Same journal

Inaccurate and inadequate ICD-10 coding related to female sexual health threatens patient care, research, and billing.

The journal of sexual medicine·2026
Same journal

Suppression of Ephx2 in endothelial cells of penile cavernouse tissue improves SHR erectile function.

The journal of sexual medicine·2026
Same journal

Concordance between self-assessment using watercolor illustrations and clinical examination: implementing a visual tool to improve recognition and communication on female genital mutilation/cutting.

The journal of sexual medicine·2026
Same journal

Recurrent self-amputation after successful penile replantation in a psychiatric patient.

The journal of sexual medicine·2026
See all related articles
This summary is machine-generated.

Phosphodiesterase type 5 (PDE5) inhibitors and central enhancers like apomorphine are key in treating erectile dysfunction. Further research is needed for improved pharmacotherapies.

Area of Science:

  • Pharmacology
  • Urology
  • Sexual Medicine

Background:

  • Advances in understanding penile erection physiology and biochemistry have driven pharmacotherapy breakthroughs for erectile dysfunction (ED).
  • Current treatments focus on molecular and cellular mechanisms of action for centrally and peripherally acting drugs.

Purpose of the Study:

  • To provide guidelines on the state-of-the-art knowledge regarding the mechanisms of action of drugs used in ED pharmacotherapy.
  • To consolidate expert opinion on the molecular and cellular basis of ED drug efficacy.

Main Methods:

  • An international consultation involving over 200 multidisciplinary experts from 60 countries over two years.
  • Expert opinions were formed through grading evidence-based literature, committee discussions, and public debates.

Related Experiment Videos

  • A dedicated committee of 25 experts from 10 countries focused on pharmacotherapy for erectile dysfunction.

    • Main Results:

    • Oral phosphodiesterase type 5 (PDE5) inhibitors exhibit high affinity for the PDE5 enzyme, blocking cyclic guanosine monophosphate (cGMP) access and facilitating smooth muscle relaxation.
    • PDE5 inhibitors, varying in potency and pharmacokinetics, elevate cGMP levels post-sexual stimulation.
    • Centrally acting drugs, such as the dopamine (D2) receptor agonist apomorphine, enhance sexual behavior by acting on the hypothalamus.

    Conclusions:

    • Further research is essential for developing innovative central and peripheral pharmacotherapeutic agents for safe and effective erectile dysfunction treatment.
    • The current understanding highlights the distinct mechanisms of PDE5 inhibitors and central enhancers in ED management.